This is massive news! I dont have access to the full article, but here is a quick summary
"Japanese drug major Astellas Pharma (TYO: 4503) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Astellas noted that this makes Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world.
Why is this such big news?
https://www.thepharmaletter.com/article/astellas-gets-first-approval-for-vyloy-in-japan?mc_cid=b0fef19e05
https://www.pharmaceutical-technology.com/news/astellas-secures-approval-for-gastric-cancer-antibody-in-japan/?cf-view
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 443503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 424264 | 6 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| ALA (ASX) Chart |